METHOD OF PRODUCING ANTIBODIES TO NON-IMMUNOGENIC MOLECULES

Abstract: Antibodies are produced that are specific for (i.e., undergo a specific binding reaction with) molecules that are not normally immunogenic. The method comprises first administering to the mammal a sensitizing agent (either the non-immunogenic molecule or a molecule which has a specific binding site for the non-immunogenic molecule) in order to elicit in the mammal an immune-attenuating response specific for the sensitizing agent. After eliciting the immune-attenuating reaction, an immunosuppressing treatment is administered to suppress the mammal's immune-attenuating response to the sensitizing agent. Having thus suppressed the mammal's immune-attenuating response, sensitizing agent is administered again, and antibody is produced and recovered from the mammal.

Description: "Method " o£ producing antibodies to non-immunogenic molecules" Background of the Invention This invention relates to antibodies and to methods of making them. Antibodies raised by conventional techniques to a relatively potent antigen such as dinitrophenyl (DNP) will bind to relatively few specific sites on the antigen. Kipps et al. (1978) Proc. Nat'l. Acad. Sci. _7_5: 2914-2917 report that they can increase the number of DNP sites recognized and the amount of DNP antibody produced by diminishing suppressor T-cell activity in mice before they immunize the mice with DNP. Matthew and Patterson ["The Production of Monoclonal Antibody that Blocks the Action of a Neurite Outgrowth-Promoting Factor" in Cold Spring Harbor Symposia on Quantitative Biology XLVIII Cold Spring Harbor Laboratory, 1983] disclose antibodies that differentiate between wild-type, functional neurite-promoting growth factor (NPF) and a mutant, non-functional form of that factor (m-NPF) . Specifically, antibodies to NPF or m-NPF normally recognize sites common to both molecules. To produce antibodies that recognize a site present on NPF but not m-NPF, mice were first immunized with preparations containing m-NPF. Then the mice were treated with an immunosuppressant drug (cyclophosphamide) to suppress the immune response to mNPF. Spleens were removed from the treated animals and spleen cells sensitized i^ vitro with preparations containing normal NPF. This procedure yielded antibodies which recognized and inhibited the neurite outgrowth activity of normal NPF. Certain molecules tend not to cause an immunogenic response; such molecules include, for example, functional sites of enzymes and other proteins with highly conserved structures, including hormones, other regulatory molecules, cell surface receptors, certain viral coat proteins, and ubiquitous molecules such as glycosaminoglycans and proteoglycans. It would be extremely useful to produce antibodies which bind such non-immunogenic molecules in order to perform various procedures such as immuno-purifications, immunoassays, or selective immuno-delivery of active molecules. Summary of the Invention The invention features, in general, producing antibodies which are specific for (i.e., undergo a specific binding reaction with) molecules that are not normally immunogenic. By describing these molecules as "not normally immunogenic or non-immunogenic", I mean that they do not cause the production of detectable or recoverable levels of cognate antibodies in normal mammals that are immunologically challenged with them. The method comprises first administering to the mammal a sensitizing agent (either the non-immunogenic molecule or a molecule which has a specific binding site for the non-immunogenic molecule) in order to elicit in the mammal an immune-attenuating response specific for the sensitizing agent. The term "specific binding site" includes binding or recognition sites of enzyme/substrate pairs, hormone/receptor pairs, or antigen/antibody pairs. After eliciting the immune-attenuating reaction, an immunosuppressing treatment is administered to suppress the mammal's immune-attenuating response to the sensitizing agent. Having thus suppressed the mammal's immune-attenuating response, sensitizing agent is administered again, and antibody is produced and recovered from the mammal. In preferred embodiments, mice are immunized with the non-immunogenic agent, i.e., glycosaminoglycans or proteoglycans such as heparin and hyaluronate, or a synthetic molecule which is non-immunogenic such poly-fucose. The mammals are then immunosuppressed by administering an agent such as cyclophosphamide that is toxic to suppressor T-lymphocytes, and the same sensitizing agent is readministered. The antibodies can be anti-idiotypic antibodies, which can be produced when the non-immunogenic molecule is a first member of a specific binding pair, and the sensitizing agent includes the second member of that pair (or an analog of it) . Also in preferred embodiments, a hybridoma is formed from an antibody-producing cell of the mammal, and the hybridoma is cultured to produce the antibody in monoclonal form. The invention enables production of antibodies which are able to bind molecules that do not normally elicit an immune response sufficient to make antibody production possible. Specific types of such non-immunogenic molecules are highly conserved enzymes, hormones or other regulatory molecules, cell surface receptors, ubiquitous molecules such as glycosaminoglycans and proteoglycans, or certain viral coat proteins. Other features and advantages of the invention will be apparent from the following description of the preferred embodiment and from the claims. Description of the Preferred Embodiments I now describe the preferred embodiments after first briefly describing the drawings. Figures 1-3 are flow charts of antibody production processes. Immunization and Cyclophosphamide Treatment Fig. 1 is a flow chart of the steps in the process for producing antibodies. Specifically, monoclonal antibodies which recognize two non-immunogenic glycosaminoglycans (GAG) , chondroitin sulfate and heparin, are made by the following procedure. Six week old female BALB/c mice are immunized intraperitoneally with 1.0 mg of chondroitin sulfate (whale and shark cartilage, Sigma Chemical Co., St. Louis) , and 1.0 mg of porcine heparin (Sigma) attached to positively charged control pore glass (treated with aminopropyltriethoxysilane) , suspended in Freund's complete adjuvant. After 24 hours, the mice are injected intraperitoneally with 100-150 mg/kg of the immunosuppressant drug, cyclophosphamide (Cytoxan, Mead Johnson) in saline. After an additional 13 days, 0.5 mg of each GAG in saline is injected intravenously. Three days after the second immunization, the spleens of the sensitized-immunosuppressed-sensitized animals are removed and hybridomas are made by fusing antibody-producing cells to NS1 myeloma cells using standard techniques, such as those described by Koehler and Milstein Nature (London) 256:495 (1975) . Hybridomas producing the desired antibodies are screened by solid phase radioimmunoassay and immunohistochemistry. Fig. 2 illustrates generally a method for making an anti-idiotypic antibody which recognizes a non-immunogenic enzyme or a non-immunogenic ligand which is part of a binding pair (e.g. a hormone/receptor pair or other specific binding pairs) . The method is specifically illustrated by making anti-idiotypic antibodies which recognize bacterial and mammalian hyaluronidase using 1.0 mg hyaluronate attached to the positively charged control pore glass for the first immunization, and using 1.0 mg of hyaluronate in saline in the second immunization. The monoclonal antibodies obtained are able to recognize hyaluronidase as evidenced by the fact that hyaluronate inhibits antibody binding to hyaluronidase; the antibodies are able to inhibit the enzymatic activity of hyaluronidase by at least 25%, and the antibodies are able to recognize both mammalian and bacterial hyaluronidases. It is possible to use the same procedure to recover both the primary antibody and the anti-idiotypic antibody, and thus obtain antibodies to both an enzyme and its substrate. Fig. 3 illustrates the use of poly-fucose (specifically fucoidan, a sulfated poly-fucose from algae) as a sensitizing agent to recover primary antibodies (Ab,) that bind to fucose as well as secondary or idiotypic antibodies (Ab 2 ) that recognize the enzyme fucosidase or fucose-specific plant lectins. Specifically, anti-idiotypic antibodies which bind to fucose-specific plant lectins and fucosidase are made by the above method using 1.0 mg fucoidan (Sigma) attached to the positively charged control pore glass as a sensitizing agent in the first immunization and 1.0 mg of fucoidan in saline as a sensitizing agent in the second immunization. The fucose-binding monoclonal antibodies (Ab,) are obtained by screening hybridomas with polyfucose. The monoclonal antibodies (Ab 2 ) that bind to fucosidase and fucose-binding plant lectin are obtained by screening with plant lectins. The anti-idiotypic antibodies are able to bind fucose-specific plant lectins as well as mammalian fucosidase. In competitive binding assays, fucose inhibits the anti-idiotypic antibody from binding to lectins. A hybridoma cell line has been prepared by the above technique using hyaluronate as the sensitizing agent. The antibodies produced by that cell line recognize hyaluronidase. A hybridoma cell line has also been prepared by the above techniques using polyfucose as a sensitizing agent. The antibodies produced by that cell line recognize fucosidase as well as fucose-specific plant lectins. A specimen of each cell line will be deposited with a public depository and 5 restrictions on availability to the public removed upon issuance of a patent on this application. The specimens will be replaced if they become non-viable for a period extending at least as long as the life of such patent, or five years after the last public request for the - ■ - deposit, whichever is longer. Use The above-described antibodies are useful in conventional immunopurification and in conventional immunoassays. 15 Other Embodiments The method described can be used to raise antibodies to other non-immunogenic molecules, particularly to other glycosoaminoglycans. The method can also be used to raise anti-idiotypic antibodies that 20 specifically bind to other enzymes, and that can be used to assay for or to purify those enzymes. Other immunosuppression treatments can be used such as thymectomizing the mammal, exposing the mammal to radiation, or administering other immunosuppressing 25 agents that are cytotoxic to lymphocytes, particularly T-lymphocytes. Other mammals, e.g., rats, can be used. When generating anti-idiotypic antibodies, the sensitizing agent can be a specific binding partner (or an analog of a specific binding partner) to the non-immunogenic molecule.

Claims: - 7 - CLAIMS 1 1. A method for producing an antibody specific for a non-immunogenic molecule comprising: 3 a) administering to a mammal a sensitizing 4 agent comprising said non-immunogenic molecule or a molecule having a specific binding site for said - non-immunogenic molecule, thereby eliciting in said 7 mammal an immune-attenuating response specific for said - sensitizing agent, 9 b) suppressing said immunogenic-attenuating 1° response in said mammal, 11 c) thereafter administering a said sensitizing 12 agent to said mammal, and 13 d) recovering antibody specific for said 4 non-immunogenic molecule. 1 2. The method of claim 1 wherein said 2 suppressing treatment comprises thymectomizing said mammal, exposing said mammal to radiation, or 4 administering an immunosuppressing agent to said mammal. - • 3. The method of claim 1 wherein said suppressing step comprises administering an immune-suppressing agent to said mammal. 1 4. The method of claim 3 wherein said 2 immunosuppressing agent is cytotoxic to lymphocytes. - ■ 5. The method of claim 4 wherein said 2 immunosuppressing agent is cytotoxic to suppressor T-lymphocytes. 1 6. The method of claim 3 wherein said immunosuppressing agent is cyclophosphamide. 7. The method of claim 1 or 3 wherein said non-immunogenic molecule is a glycosaminoglycan or a proteoglycan. 8. The method of claim 1 or 3 wherein said non-immunogenic molecule is heparin, hyaluronate, or poly-fucose. 9. The method of claim 1 or 3 wherein said mammal is a mouse or a rat. 10. The method of claim 1 or 3 wherein the sensitizing agent used .in step c) is the same as the agent used in step a) . 11. The method of claim 1 or claim 3 in which the step of recovering said antibody comprises forming a hybridoma cell line from an antibody-producing cell of said mammal, and culturing said hybridoma to generate said antibody in monoclonal form. 12. The method of claim 1 or 3 wherein said antibody is an anti-idiotypic antibody. 13. The method of claim 12 wherein said non-immunogenic molecule is a first member of a specific binding pair, and said sensitizing agent is the second member of said pair or an analog of said second member. 14. The method of claim 13 wherein said sensitizing agent is heparin, hyaluronate, or poly-fucose. 15. The method of claim 14 wherein said anti-idiotypic antibody binds to mammalian fucosidase, or mammalian or bacterial hyaluronidase. 16. An antibody produced by the method of claim 1 or 3. 17. A hybridoma produced by the method of claim 11.

Inventors: MATTHEW WILLIAM D, MATTHEW, WILLIAM, D.
Applicants: HARVARD COLLEGE, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Application year: 1986
Main classification: C12P21
IPC codes: C07K16